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Purpose: To quantify misclassification in glucocorticoid (GC) exposure defined
using UK primary care prescription data.
Methods: A cross‐sectional study including patients with rheumatoid arthritis
prescribed oral GCs in the past 2 years. Glucocorticoid exposure based on electronic
prescription records was compared with participant‐reported GC use captured using a
paper diary. Prescription data (containing information about prescriptions issued but
no dispensing information) was provided by the Clinical Practice Research Datalink.
The following variables were defined: current use and dose of oral GCs and if (and
when) participants had received a GC injection. For oral GCs, self‐reported use was
taken to represent “true” exposure. A dataset representing a hypothetical population
was generated to assess the impact of the misclassification found for current use.
Results: A total of 67 of 78 study participants (86%)were correctly classified as currently
on/off oral GCs; 32/38 (84.2%) participants reporting current GC use and 35/40 (87.5%)
participants not reporting current use were correctly classified. Estimated values of current
dose were imprecise (correlation coefficient 0.46). Concordance between reported and
prescribed GC injections was poor (kappa statistic 0.14). Misclassification bias was demon-
strated in the hypothetical population: For “true” relative risks of 1.5, 4, and 9, the
“observed” relative risks were 1.33, 2.48, and 3.58, respectively.
Conclusions: Misclassification of current use of oral GCs was low but sufficient to
lead to significant bias. Researchers should take care to assess the likely impact of
exposure misclassification on their analyses.
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KEY POINTS
• Glucocorticoid exposure defined using UK electronic
prescription data (prescriptions issued) was compared
with participant self‐report, taking self‐report to
represent true exposure
• Current use of oral glucocorticoids was correctly
classified for 86% of participants, with a false positive
rate of 6.4% and false negative rate of 7.7%
• Estimates of daily dose were not significantly biased but
were imprecise, with a mean (SD) absolute difference
between estimated and reported dose of 3.2 (4.2) mg
(prednisolone equivalent)
• Concordance between prescribed and reported
glucocorticoid injections was low (κ = 0.14) indicating
primary care prescription data alone are not a reliable
source of information about glucocorticoid injections
2 JOSEPH ET AL.1 | INTRODUCTION
Databases of UK primary care electronic health records (EHR), such as
the Clinical Practice Research Datalink (CPRD), are commonly used for
pharmacoepidemiological research, including drug safety or effective-
ness studies.1 Such studies aim to estimate the association between
exposure to a particular medication and a beneficial or adverse out-
come. The accuracy of such an estimate is affected by how accurately
the variables of interest are measured.
In a drug safety or effectiveness study, the underlying exposure of
interest is actual intake of the drug by patients.2 For studies set within
UK primary care EHR, drug exposure is typically defined using
information about prescriptions issued to patients. Estimates of drug expo-
sure based on primary‐care prescriptions are only a proxy measure of true
drug exposure, and there are numerous reasons why such estimates may
differ from actual drug intake. Such datasets do not capture medication
accessed outside of primary care, including drugs issued in a hospital setting
or over the counter.3 In addition, prescription data do not reveal whether
the patient filled that prescription or took the medication as prescribed.
Differences between true and estimated drug exposure (known as
exposure measurement error or misclassification) can lead to misclassifi-
cation bias, potentially masking the true association between the drug
and outcome of interest.2 While there have been numerous studies
validating diagnoses in UK primary care research databases,4 the accu-
racy of measurements of drug exposure have been largely unexplored.
Similarly, most pharmacoepidemiology studies recognise the potential
for exposure misclassification,5,6 but few attempt to quantify the extent
or impact of the resulting errors7,8 or correct for such errors.9
The purpose of this study was to quantify errors in the measurement
of glucocorticoid (GC) exposure based on UK primary care prescription
data. Glucocorticoids are an interesting example due to multiple and
sometimes complex prescribing patterns and the possibility of secondary
care prescribing. In addition, GCs are associated with a range of side
effects,10 whichmay lead to nonadherence toGC regimes by patients.11,12
Exposure to GCs estimated using primary care prescription data
was compared with patient‐reported GC use captured using diaries.
The objective was to quantify misclassification in estimations of
current use of oral GCs. Misclassification in daily dose and in GC injec-
tions was also explored. The impact and importance of this misclassi-
fication was demonstrated using a generated dataset representing a
hypothetical population with levels of exposure misclassification
informed by the results of the main study.2 | METHODS
2.1 | Design and setting
This analysis was conducted as part of a study investigating GC use and
adrenal insufficiency in patients with rheumatoid arthritis (RA) (the
“SAIRA” study).13This was a cross‐sectional study with data collection
nestedwithin UK primary care EHR. Participants were recruited through
general practices across England. Between October 2015 and April
2016, participants collected a saliva sample and completed a diary pro-
viding information about their current and past use of GCs. The presentanalysis makes use of the information collected in the diaries. This infor-
mation was combined with EHR data provided by the CPRD.14
The study was approved by the NHS National Research Ethics
Service Committee London‐Bromley (reference 14/LO/1335) and the
Independent Scientific Advisory Committee (reference 14_145RA).
2.2 | Clinical Practice Research Datalink
Clinical Practice Research Datalink is a database of pseudonymised UK
primary care electronic health records. General practices contribute infor-
mation prospectively to CPRD. Information captured includes demo-
graphic characteristics, symptoms and diagnoses, and all prescriptions
issued by the general practices. Clinical Practice Research Datalink pro-
vided the complete, depersonalised, EHR for the participants in this study,
as of June 2016. The design of the study precluded linkage of CPRD data
to identifiable patient data, except by the relevant general practice.13
2.3 | Participants
For the SAIRA study,13 eligible participants were patients with RA (iden-
tified within CPRD using a validated algorithm15), over the age of 16,
registered at an English general practice, prescribed oral GCs within
2 years of the study, and had no record of any conditions or medications
known to affect adrenal function. All participants had at least 2 years of
follow‐up within CPRD. Potentially eligible patients were screened for
suitability by their GP. General practices mailed invitations to potential
participants. Participants were recruited by the study team at the
University of Manchester and provided written consent to take part.
2.4 | Self‐reported GC use
Paper‐based diaries were used to collect information about GC use
from participants (see Supplementary S1). Participants completed the
diaries at home on a single occasion, shortly after waking and before
taking any GCs. An illustrated list of possible GC tablets was provided
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use were left blank this was interpreted as no use. The following var-
iables were defined using the diaries: exposed/not exposed to oral
GCs in the past 24 hours; total dose of oral GCs (mg, prednisolone
equivalent dose) taken in the past 24 hours; ever given a GC injection;
and number of months since last GC injection.
2.5 | Prescribed GC use
Prescriptions for oral and injected GCs were identified within the
EHR provided by CPRD. The available data represent written prescrip-
tions rather than filled prescriptions. A record is generated for each pre-
scription written, including each prescription refill. Code lists for oral and
injectedGCswere generated by identifying all products corresponding to
the British National Formulary16 chapter 6.3.2 (“Glucocorticoid therapy”)
within the product dictionary provided by CPRD and by searching the
dictionary using a prespecified list of drug substances. To determine
whether a patient had an active prescription on a particular date, it was
necessary to define the start and end of each prescription. For this, we
used an algorithm17 that takes into account multiple sources of duration
information within CPRD and accounts for overlapping prescriptions
(Supplementary S2). The daily dose of GCswas calculated as the strength
multiplied by the number of tablets per day. Doses were converted to
prednisolone‐equivalent dose.
2.6 | Participant characteristics
The following demographic characteristics were defined using the
CPRD data: gender, age, and socio‐economic status (SES) defined
using the Townsend score.18 Socio‐economic status information is
provided as a linked dataset by CPRD and is missing for general prac-
tices that have not agreed to the linkage (approximately 45% of CPRD
practices). Duration of RA was calculated from the date the partici-
pants first met the criteria for RA according to the algorithm.15
2.7 | Analysis
Characteristics of the study population on the diary date were
summarised using proportions or the median and interquartile range (IQR).
Misclassification in oral GC use (currently/not currently exposed)
was quantified by comparing self‐reported GC with the status deter-
mined from the prescription data. Self‐reported use was taken to be
the true exposure. The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were determined. Exact
(binomial) confidence intervals (CIs) were calculated. Difference tests
(Kruskal‐Wallis and chi‐squared tests) were used to investigate possi-
ble associations between participant characteristics and misclassifica-
tion of current GC use.
Daily dose according to self‐report and the prescription data were
summarised. Scaled normal density plots were drawn to visualise
the distributions of the two measures of daily dose. Measurement
error in continuous variables consists of a systematic error (bias) and
subject error (precision).2 Taking self‐reported dose to be true expo-
sure, bias was assessed by the difference between the means of the
two measurements, with 95% CIs. The Spearman rank correlation
coefficient was calculated to estimate concordance between the doseestimated from prescription data and the “true” reported dose. The
mean (standard deviation, SD) absolute difference between the two
measurements was calculated as a measure of precision. Results were
calculated for all participants and then including only participants
correctly classified as current users.
Finally, whether participants ever received a GC injection accord-
ing to self‐report or the prescription data were compared, using
Cohen kappa statistic to measure concordance (neither measurement
was judged to be the “true” exposure). The timings of the most recent
GC injection according to both measures were summarised.
To demonstrate the potential impact of exposure misclassifica-
tion at the population level, a dataset representing a hypothetical
population was generated using Stata. A dataset of 100 000 obser-
vations was generated and “true” exposure (binary) was set to
50%. “Observed” exposure was then generated, conditional upon
the true exposure and the sensitivity and specificity found in the
main study. Nondifferential misclassification was assumed. An
outcome variable was then generated conditional upon the true
exposure and independent of the observed exposure. The relative
risk (RR) for observed exposure was calculated (details in Supple-
mentary S3).
All data cleaning and analyses were performed using Stata/MP
13.1 (StataCorp LP, Texas).3 | RESULTS
For the SAIRA study, invitations were sent to 526 patients, 117 partici-
pants were recruited, and 86 participants returned their diaries (the full
flow of participants has been described previously13). All of these
86 participants are included in the present analysis. The numbers and
characteristics of patients at various stages of recruitment are shown in
Supplementary S4: Participants were similar to the whole eligible popula-
tion in terms of age and gender but tended to be of a higher SES. One
participant did not provide a diary completion date, and a further seven
were excluded as the last data uploaded by their practice preceded the
diary completion date. Of the remaining 78 participants, 72% of
participants were female, the median age was 68 years (range, 28‐89),
and the median duration of RA was 7.7 years (Table 1).3.1 | Oral GCs: Current use
Out of 78 participants, 38 (49%) reported currently taking oral GCs on
the diary completion date while 37 (47%) had an active prescription
for oral GCs. Using the prescription data, 32 of the 38 participants
reporting current use and 35 of the 40 participants not reporting
current use were correctly classified (Figure 1). Therefore, using the
prescription data to predict patient‐reported current GC use the
sensitivity was 84.2% (95% CI, 68.7‐94.0%) and the specificity
was 87.5% (95% CI, 73.2‐95.8%) (Figure 1). The PPV was 86.5%
(71.2‐95.5%), and the NPV was 85.4% (70.8‐94.4%). Overall, the cur-
rent GC exposure statuses of 67 (86%) participants were correctly
classified in the prescription data compared with self‐report. There
were no obvious differences in participant characteristics between
those correctly classified and misclassified (Table 1).
TABLE 1 Participant characteristics on index date according to classification of current use of oral GCsa
All Correctly Classified Misclassified Difference Test
Number of participants 78 67 11 …
Female, n (%) 56 (71.8) 48 (71.6) 8 (72.7) χ2 (1)=0.01, P = 0.941
Age, median (IQR) 68 (60‐75) 68 (61‐74) 61 (49‐76) KW (1)=0.90, P = 0.343
Townsend score quintile, median (IQR) (1 = least deprived) 2 (2‐3) 2 (2‐3) 2.5 (1.5‐3.5) χ2 (4)=0.73, P = 0.948
RA duration (years), median (IQR) 7.7 (2.8‐10.4) 7.8 (3.6‐10.4) 5.3 (1.9‐20) KW (1)=0.21, P = 0.651
Cumulative oral GC dose (g)b, median (IQR) 2 (0‐4) 1.8 (.4‐4.4) 2.3 (1.3‐3.3) KW (1)=0.11, P = 0.736
Percentage of time on oral GCsb, median (IQR) 45% (8‐93%) 45% (793%) 50% (9‐95%) KW (1)=0.09, P = 0.769
Abbreviations: GC, glucocorticoid; IQR, interquartile range; KW, Kruskal‐Wallis test; RA, rheumatoid arthritis.
aTownsend score was missing for nine participants.
bIn the previous 2 years, according to prescription data.
FIGURE 1 Misclassification matrix for current use of oral
glucocorticoids. Current use (exposed vs unexposed) according to
prescription data is compared with current use according to patient
self‐report. The figure shows the percentages of patients in each
category, according to self‐report, who were correctly classified or
misclassified in the prescription data.
TABLE 2 Mean dose of oral GCs according to self‐report and pre-
scription dataa
All Participants
(n = 78)
Current GC
Users (n = 32)
Mean (SD)
reported dose, mg
3.4 (4.9) 6.6 (3.2)
Mean (SD)
prescribed dose, mg
3.6 (5.3) 7.6 (5.8)
Mean (SD)
absolute difference, mg
2.4 (4.7) 3.2 (4.2)
aValues are shown for all participants (n = 78) and for those who were
correctly classified as current GC users (n = 32). GC, glucocorticoid; SD,
standard deviation.
FIGURE 2 Scaled normal density plots for daily dose of oral
glucocorticoids according to prescription data (A) and self‐report (B).
The dashed vertical lines are the sample means.
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The estimated current daily dose matched the reported dose for 42
of the 78 participants; this includes the 35 participants who were cor-
rectly classified as noncurrent users (hence with a daily dose of 0 mg).
The estimated dose was greater than the reported dose for 20 partic-
ipants and less than the reported dose for 16 participants. The mean
reported and prescribed daily doses are presented in Table 2. Overall,
the bias (mean difference) was 0.2 mg (95% CI, −1.0 to 1.4 mg), the
mean (SD) absolute difference between the prescribed and reported
dose was 2.4 (4.7) mg, and the Spearman correlation coefficient was
0.70 (P < 0.001).
Considering only the 32 participants correctly classified as cur-
rent oral GC users, the estimated daily dose matched the reported
daily dose for seven participants, was an overestimate for 15 partic-
ipants, and was an underestimate for 10 participants. For this subset
of participants, the bias was 1.0 mg (95% CI, −0.9 to 2.9 mg). The
mean (SD) absolute difference in dose values was 3.2 (4.2) mg,and the Spearman correlation coefficient was 0.46 (P = 0.009). The
distributions of the two measures of daily dose for these 32 partic-
ipants are shown in Figure 2; this figure highlights the small differ-
ence in the means but larger variance in the daily dose estimated
from prescription data.
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Excluding one participant who reported an injection but was unsure
whether it was GC, 48 of 77 (62%) reported ever having a GC injec-
tion and 34 (44%) had a GC injection in their primary care prescription
records. Of the 48 participants reporting a GC injection, 24 (50%) had
no GC injection in their prescription records, while 10 (34%) of the 29
participants who did not report a GC injection did have a GC injection
in their prescription records (Figure 3). The kappa statistic for concor-
dance between the datasets was 0.14 (95% CI, −0.06 to 0.34), indicat-
ing little to no agreement. Reported injections were on average more
recent than prescribed injections, a median of 0.7 (range 0‐8.5) years
ago compared with 2.7 (range 0‐24) years ago.3.4 | Impact of misclassification
The sensitivity and specificity found for current use of oral GCs
(84.2% and 87.5%, respectively) were applied to the hypothetical
population generated using Stata. In this dataset, while the “true”
exposure rate was set to 50%, the “observed” exposure rate was
48.4%. The RR of the outcome according to the true exposure classi-
fication was varied. For true RRs of 1.5, 4, and 9, the observed RRs
were 1.33, 2.48, and 3.58, respectively.4 | DISCUSSION
This study aimed to quantify errors in the measurement of exposure
to oral GCs based on UK primary care prescription data. Agreement
between self‐reported use of oral GCs and use estimated from pre-
scription data was high: 86% of participants were correctly classified
as current or noncurrent users using the prescription data. However,
the hypothetical study demonstrated that this level of misclassification
can lead to important bias. A real study would also involve sampling
variation around the population RR.
On average, estimates of current daily dose were not significantly
biased. For current GC users, the estimates of dose were on averageFIGURE 3 Self‐reported vs prescribed GC injections. Cross‐
tabulation of ever receiving a GC (glucocorticoid) injection according
to self‐report or primary care prescription records.1 mg (prednisolone equivalent) higher than the reported doses.
However, agreement between the two measurements was fairly low
(Spearman correlation coefficient 0.46), and the mean (SD) absolute
difference was 3.2 (4.2) mg. This measurement error could introduce
bias in analyses, as even low levels of imprecision can lead to bias
towards the null (eg, page 80 in White 20052).
Concordance between self‐reported and prescribed GC injections
was very low, with a kappa statistic of 0.14 and confidence intervals
crossing 0. In this case, neither measurement was considered to be
more accurate than the other. Patients' recall of historical injections
is unlikely to be accurate, while injections given in secondary care will
not be captured in the primary care prescription records.
Previous studies have predominately validated pharmacy dispens-
ing data rather than prescription data. These studies have reported
levels of misclassification varying according to the class of medica-
tion.19-21 One previous study attempted to validate prescriptions of
low‐dose aspirin using data from The Health Improvement Network
(THIN), which, like CPRD, captures UK primary care data22; this study
collected additional information from general practices in order to
estimate misclassification due to over‐the‐counter prescribing of aspi-
rin. To our knowledge, the current study is the first CPRD study to
attempt to validate prescription‐based estimates of drug exposure.
There are several reasons why GC exposure estimated using
primary care prescription records may differ from true drug exposure.
First, primary care records may not capture all medications to which
patients have been exposed. Glucocorticoids prescribed in other
health care settings, such as rheumatology clinics, are not typically
captured in primary care EHR.3 Second, receiving a prescription does
not guarantee the patient will take their medications as prescribed.
Glucocorticoids are associated with a range of side effects that
matter to patients and are likely to affect adherence.10,12,23 In addi-
tion, studies able to link prescribing and dispensing data have demon-
strated that a high proportion of prescriptions are never filled by
patients.24,25 Third, studies set within EHR are reusing data originally
collected for purposes other than research. Preparing such datasets
for research typically involves making a number of assumptions about
the data. The current study used an algorithm to estimate the duration
of individual prescriptions based on any duration information provided
by the GP. These data processing steps can influence the rate of mis-
classification in the final dataset. van Staa et al26 demonstrated how
decisions about exposure duration can impact the degree of misclassi-
fication. This has subsequently been demonstrated in a number of
observational studies.27-30
There is little literature regarding the definition of dose from pre-
scription data, but it is likely that the measurement error found in the
current study was influenced by the quality of the dosage information
available in the EHR, patient adherence, and data preparation deci-
sions. The variable used to define dose is derived from free text by
CPRD and reflects the average daily dose for a prescription. Compli-
cated dosage regimens (eg, tapering schedules) will not be closely
reflected in the final dataset. Potentially, the estimated dose could
reflect the average dose taken by patients more closely than it does
the dose taken on a particular day. It was not possible to examine
this in our data, although a subset of participants (10 of 78) reported
a variable dose throughout the week.
6 JOSEPH ET AL.In order to quantify misclassification in estimates of true drug
exposure based on primary care prescription data, it was necessary
to compare estimates to an alternative data source. There are no per-
fect measures of true drug exposure: only direct observation or mea-
surement of active drug in biological samples can guarantee a drug
has been taken, yet these approaches add significantly to the cost
and complexity of a study.2 Participant self‐report was chosen as a
pragmatic source of drug exposure data. There are recognised chal-
lenges with self‐reported medication use, and it is possible that the
self‐reported data will also differ from true exposure. The diary was
designed to minimise the risk of common sources of errors. To limit
errors in recalling use of oral GCs, a short recall period (24 h) was used
and an illustrated list of the medications of interest was provided. To
reduce the likelihood of errors due to social desirability bias,31 partic-
ipants were assured that their responses were confidential. However,
there is a residual risk error in the participant‐reported dataset. The
study exclusion criteria did not consider factors potentially related to
medication self‐report or adherence (eg, cognitive impairment or
depressive symptoms), although ability to give informed consent was
one of the screening criteria used by GPs. While acknowledging the
residual risk of errors, we considered self‐reported of oral GCs to be
a more accurate measurement of true drug exposure than prescrip-
tion‐based estimates. As described above, there are many potential
sources of error in prescription‐based estimates, and in the majority
of cases, patients have the ultimate responsibility for taking their
medications. Self‐reported medication exposure has been used as
the reference standard in a number of previous studies validating
routinely collected drug exposure data.20,27,30 Specifying a reference
standard allowed rates of misclassification in estimated GC exposure
to be calculated, rather than simply concordance between the
datasets. For GC injections, we asked participants to recall injections
over a long period, and thus, this data is likely to contain errors; self‐
reported injections were therefore not considered to be more reliable
than the prescription data.
A limitation of the study is the small sample size and the likelihood
of selection bias: as well as influencing the generalisability of the
results, it is likely that the estimated rates of misclassification will be
biased. The participants in this study may differ in their medication
adherence compared with nonparticipants and taking part in the study
may have altered the participants' normal drug‐taking behaviour.
Overall, we believe the study population are likely to have higher rates
of adherence compared with the general population and therefore
that the rates of misclassification reported in this study are likely to
be an underestimate. Furthermore, as discussed earlier, multiple fac-
tors influence the likelihood of misclassification, including the particu-
lar drug studied.19,30 As the current study focussed on one particular
drug class (GCs) and a particular patient population (patients with RA
willing to take part in research), these results are not necessarily
generalisable beyond this particular setting. Furthermore, this study
included patients with established RA taking on average low GC
doses: in early RA and other diseases higher GC doses and more com-
plex treatment regimens may be used. However, the results are useful
as they exemplify the problem of misclassification. Finally, the esti-
mated levels of measurement error and the hypothetical study rely
on the assumption that self‐report is an accurate measure of drugexposure. Any errors in the quantification of misclassification will
affect the results of the hypothetical study.
With these caveats in mind, the results of this study suggest that
researchers using these datasets need to consider the potential impact
of exposure misclassification on their analyses. Techniques exist to
account for misclassification in analyses whether or not validation
data are available (see Corbin et al32). If a quantitative approach is
not used to assess bias, results should be presented cautiously without
underplaying the risk of misclassification bias.33
In conclusion, when using UK primary care prescription data to
define exposure to GCs and assuming participant self‐report to
represent true exposure, the rate of misclassification of current use
of oral GCs was low, but sufficient to lead to important misclassifica-
tion bias in our hypothetical example. Measurement error was high
for both current dose of oral GCs and exposure to GC injections,
and primary care prescriptions may not be reliable as the sole data
source for GC injections. Researchers using prescription data to
define drug exposure should, as a minimum, consider the risk of
measurement errors and the likely impact of misclassification bias
on their analyses.
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